Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes
- 1 February 2012
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 81 (2), 123-135
- https://doi.org/10.1016/j.critrevonc.2011.02.007
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNetJournal of Clinical Oncology, 2009
- First‐line therapy for chronic myeloid leukemia: Past, present, and futureAmerican Journal of Hematology, 2009
- Chronic Myeloid Leukemia: An Historical PerspectiveHematology, 2008
- Chronic myeloid leukaemiaThe Lancet, 2007
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysisHealth Technology Assessment, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and PrednisoneJournal of Clinical Oncology, 1999
- Lessons learned from measuring health-related quality of life in oncology.Journal of Clinical Oncology, 1994